At final assessment , mirabegron was significantly superior to placebo in terms of mean [ sd ] change from baseline in number of micturitions/24h ( -1.67 [ 2.212 ] vs -0.86 [ 2.354 ] ; P < 0.001 ) and mean [ sd ] change from baseline in number of urgency episodes/24h ( -1.85 [ 2.555 ] vs -1.37 [ 3.191 ] ; P = 0.025 ) , incontinence episodes/24h ( -1.12 [ 1.475 ] vs -0.66 [ 1.861 ] ; P = 0.003 ) , urgency incontinence episodes/24h ( -1.01 [ 1.338 ] vs -0.60 [ 1.745 ] ; P = 0.008 ) , and volume voided/micturition ( 24.300 [ 35.4767 ] vs 9.715 [ 29.0864 ] mL ; P < 0.001 ) .